Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A
Breast Cancer Res. 2019; 21(1):86.
PMID: 31370904
PMC: 6676640.
DOI: 10.1186/s13058-019-1166-4.
Pachmann K, Schuster S
Cancers (Basel). 2018; 10(11).
PMID: 30380648
PMC: 6266844.
DOI: 10.3390/cancers10110407.
Kallergi G, Agelaki S, Papadaki M, Nasias D, Matikas A, Mavroudis D
Breast Cancer Res. 2015; 17:113.
PMID: 26285572
PMC: 4541732.
DOI: 10.1186/s13058-015-0624-x.
Kuniyoshi R, Gehrke F, Alves B, Vilas-Boas V, Colo A, Sousa N
Tumour Biol. 2015; 36(10):8075-83.
PMID: 25976504
DOI: 10.1007/s13277-015-3529-5.
Freeman J, Gray E, Millward M, Pearce R, Ziman M
J Transl Med. 2012; 10:192.
PMID: 22978632
PMC: 3480925.
DOI: 10.1186/1479-5876-10-192.
Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer.
Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A
PLoS One. 2012; 7(8):e42895.
PMID: 22952619
PMC: 3428347.
DOI: 10.1371/journal.pone.0042895.
Circulating tumor cells measurements in hepatocellular carcinoma.
Chiappini F
Int J Hepatol. 2012; 2012:684802.
PMID: 22690340
PMC: 3368319.
DOI: 10.1155/2012/684802.
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.
Pachmann K, Camara O, Kroll T, Gajda M, Gellner A, Wotschadlo J
J Cancer Res Clin Oncol. 2011; 137(9):1317-27.
PMID: 21739182
PMC: 3155034.
DOI: 10.1007/s00432-011-1000-6.
Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S
Breast Cancer Res. 2011; 13(3):R59.
PMID: 21663619
PMC: 3218948.
DOI: 10.1186/bcr2896.
Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.
Pachmann K, Camara O, Kohlhase A, Rabenstein C, Kroll T, Runnebaum I
J Cancer Res Clin Oncol. 2010; 137(5):821-8.
PMID: 20694797
PMC: 3074080.
DOI: 10.1007/s00432-010-0942-4.
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki M, Strati A, Lianidou E
Breast Cancer Res. 2009; 11(6):R84.
PMID: 19919679
PMC: 2815547.
DOI: 10.1186/bcr2452.
Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
Camara O, Jorke C, Hammer U, Egbe A, Rabenstein C, Runnebaum I
J Cancer Res Clin Oncol. 2008; 135(4):643-7.
PMID: 18936973
DOI: 10.1007/s00432-008-0498-8.
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V
Breast Cancer Res. 2008; 10(5):R80.
PMID: 18822183
PMC: 2614515.
DOI: 10.1186/bcr2149.
Circulating tumor cells in breast cancer: methodology and clinical repercussions.
Gasent Blesa J, Candel V, Esteban Gonzalez E, Vidal Martinez J, Gisbert Criado R, Provencio Pulla M
Clin Transl Oncol. 2008; 10(7):399-406.
PMID: 18628068
DOI: 10.1007/s12094-008-0222-9.
[Cytomics and predictive medicine for oncology].
Gerstner A, Laffers W
HNO. 2008; 56(4):383-8.
PMID: 18351309
DOI: 10.1007/s00106-008-1703-4.
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Pachmann K, Dengler R, Lobodasch K, Frohlich F, Kroll T, Rengsberger M
J Cancer Res Clin Oncol. 2007; 134(1):59-65.
PMID: 17611779
DOI: 10.1007/s00432-007-0248-3.
